307308-74-3

Upstream product

• 119-36-8 methyl salicylate 
• 350-46-9 4-Fluoronitrobenzene 
• 1596360-95-0 2-{4-[(tert-butoxy)carbonylamino]phenoxy}benzamide 
• 1596360-94-9 2-{4-[(tert-butoxy)carbonylamino]phenoxy}benzoic acid 
• 1596360-93-8 methyl 2-{4-[(tert-butoxy)carbonylamino]phenoxy}benzoate 
• 212189-58-7 methyl2-(4-aminophenoxy)benzoate 
• 212189-50-9 methyl2-(4-nitrophenoxy)benzoate 

Downstream Products

• 1596360-57-4 methyl 6-[[3-[4-(2-carbamoylphenoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596360-07-4 2-[4-(2,4-dioxo-1,3-diazolidinyl)phenoxy]benzamide 
• 1596360-37-0 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-[4-(2-carbamoylphenoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-80-3 9H-fluoren-9-ylmethyl N-[(5S)-5-[[6-[[3-[4-(2-carbamoylphenoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]-5-cyano-pentyl]carbamate 
• 1596360-96-1 ethyl2-{[4-(2-carbamoylphenoxy)phenyl]amino}acetate 

Relevant academic research and scientific papers

Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is